文献速递血栓与止血造血干细胞移植与细胞治疗

接受病原体减少血小板与常规血小板输注的血液病患者急性肺损伤研究

Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet components.
PubMed 文献 · Blood Adv · 2024-01-01

这项前瞻性多中心开放标签序贯队列研究纳入1068例接受病原体减少血小板成分(PRPC)和1223例接受常规血小板成分(CPC)的血液病患者,评估因肺功能障碍启动的治疗中出现辅助机械通气(TEAMV-PD)发生率。PRPC组TEAMV-PD发生率为1.7%,低于CPC组的3.1%,治疗差异为-1.5%(95%CI,-2.7至-0.2)。

要点

  • PRPC组TEAMV-PD发生率为1.7%,CPC组为3.1%,治疗差异-1.5%(95%CI,-2.7至-0.2)。
  • 需要≥2次血小板输注的患者中,PRPC组TEAMV-PD较CPC组降低,治疗差异-2.4%(95%CI,-4.2至-0.6)。
  • 贝叶斯分析显示PRPC降低TEAMV-PD和TEARDS的概率分别为99.2%和88.8%。

核心结论

  • 本研究中,与CPC相比,PRPC在依赖血小板输注的血液病患者中降低需要辅助机械通气的严重肺损伤具有高概率。

研究设计与样本

  • 前瞻性、多中心、开放标签、序贯队列研究,评估因肺功能障碍启动的治疗中出现辅助机械通气(TEAMV-PD)的发生率。
  • 第一队列接受CPC,之后各中心入组第二队列接受PRPC,共1068例PRPC和1223例CPC。
  • 其他结局包括临床显著肺部不良事件(CSPAE)和经盲法专家裁定的治疗中出现急性呼吸窘迫综合征(TEARDS)发生率。
  • 试验在www.ClinicalTrials.gov注册,注册号为#NCT02549222。

主要发现

  • 全部患者中TEAMV-PD发生率PRPC组为1.7%,CPC组为3.1%,治疗差异-1.5%(95%CI,-2.7至-0.2)。
  • 需要≥2次血小板输注的患者中,TEAMV-PD发生率PRPC组较CPC组降低,治疗差异-2.4%(95%CI,-4.2至-0.6)。
  • CSPAE随血小板成分暴露增加而增加,但两队列间无显著差异。
  • 接受≥2次血小板输注的患者中,TEARDS发生率PRPC组为1.3%,CPC组为2.6%(P=.086)。
  • 贝叶斯分析显示PRPC降低TEAMV-PD和TEARDS的概率分别为99.2%和88.8%。

关键数值与推荐

  • TEAMV-PD发生率:PRPC组1.7% vs CPC组3.1%,治疗差异-1.5%(95%CI,-2.7至-0.2)。
  • 需要≥2次血小板输注者TEAMV-PD治疗差异:-2.4%(95%CI,-4.2至-0.6)。
  • 接受≥2次血小板输注者TEARDS发生率:PRPC组1.3% vs CPC组2.6%(P=.086)。
  • 贝叶斯分析PRPC降低TEAMV-PD的概率为99.2%,降低TEARDS的概率为88.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients treated with antineoplastic therapy often develop thrombocytopenia requiring platelet transfusion, which has potential to exacerbate pulmonary injury. This study tested the hypothesis that amotosalen-UVA pathogen-reduced platelet components (PRPCs) do not potentiate pulmonary dysfunction compared with conventional platelet components (CPCs). A prospective, multicenter, open-label, sequential cohort study evaluated the incidence of treatment-emergent assisted mechanical ventilation initiated for pulmonary dysfunction (TEAMV-PD). The first cohort received CPC. After the CPC cohort, each site enrolled a second cohort transfused with PRPC. Other outcomes included clinically significant pulmonary adverse events (CSPAE) and the incidence of treatment-emergent acute respiratory distress syndrome (TEARDS) diagnosed by blinded expert adjudication. The incidence of TEAMV-PD in all patients (1068 PRPC and 1223 CPC) was less for PRPC (1.7 %) than CPC (3.1%) with a treatment difference of -1.5% (95% confidence interval [CI], -2.7 to -0.2). In patients requiring ≥2 PCs, the incidence of TEAMV-PD was reduced for PRPC recipients compared with CPC recipients (treatment difference, -2.4%; 95% CI, -4.2 to -0.6). CSPAE increased with increasing PC exposure but were not significantly different between the cohorts. For patients receiving ≥2 platelet transfusions, TEARDS occurred in 1.3% PRPC and 2.6% CPC recipients (P = .086). Bayesian analysis demonstrated PRPC may be superior in reducing TEAMV-PD and TEARDS for platelet transfusion recipients compared with CPC recipients, with 99.2% and 88.8% probability, respectively. In this study, PRPC compared with CPC demonstrated high probability of reduced severe pulmonary injury requiring assisted mechanical ventilation in patients with hematology disorders dependent on platelet transfusion. This trial was registered at www.ClinicalTrials.gov as #NCT02549222.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wheeler AP, Snyder EL, Refaai M, et al. Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet components. Blood Adv. 2024. PMID: 38447116. doi:10.1182/bloodadvances.2023012425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。